I guess naked short selling doesn't exist in your world.
Why drag us back to so-called fundamentals?
Talk about valuation? How would you value MSB's families of over 500 patents? Zero?
The poster would be better served by focussing his/her energies on understanding what makes MSB unique among biotechs and what makes stem cell technology unique.
Then look a the size of the market.
Think about game changers, and then get the slicing and dicing about current revenue into perspective.
Just an idea.
What happens when ..., page-63
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |